RIBOZYME AND OMICS
GC Biopharma
(CEO Eun-Chul Huh) and MOGAM Institute for Biomedical Research (CEO Jeong
Jae-wook, hereafter referred to as MOGAM) announced on the 11th of
June that they had signed an agreement with Rznomics Inc. (CEO Lee Seong-wook)
to jointly develop a treatment for intractable diseases based on a
next-generation ribonucleic acid (RNA) platform.
This
agreement is about cooperation not only for joint research for the development
of therapeutic agents, but also for the exchange of material and human resources
necessary for the development process.
In this
process, Rznomics will be in-charge of developing next-generation technology
that can be applied to rare intractable diseases based on its own RNA platform.
Rznomics is a new drug development company based on ‘trans-ribozyme’.
Which its main
business is the development of gene therapy for cancer and intractable
diseases.
MOGAM has
the research base capability on disease mechanisms and models (in vitro/in
vivo), and will cooperate organically with Rznomics to derive drug candidates
based on the technology and research capabilities acquired through mRNA and drug
delivery research. In addition, GC Biopharma will provide resources and
know-how necessary for clinical research and commercialization.
“Through this
collaboration, we will develop next-generation RNA technology based on our
unique platform technology and spur the development of innovative
therapeutics,” said Seong-wook Lee, CEO of Rznomics.
Jung Jae-wook, head of the MOGAM institute, said, “We will work closely with collaborators to develop a treatment based on the excellent basic research capabilities of the MOGAM Institute.”
Heo
Eun-cheol, CEO of GC biopharma, said, “We will continue to seek various
opportunities for cooperation to meet unmet needs in the treatment of
intractable diseases.”